.jpg?format=webp&quality=80&width=3840)
In patients with metastatic colorectal cancer (CRC) who experience disease progression on initial chemotherapy, the standard treatment is to switch to alternative regimens such as trifluridine plus tipiracil (FTD-TPI). However, the effectiveness of combining targeted therapies with FTD-TPI has been uncertain. The phase III SUNLIGHT trial has now provided data showing that the addition of bevacizumab to FTD-TPI leads to improved outcomes for these patients. This finding suggests that combining bevacizumab with FTD-TPI could be a more effective treatment approach for patients with metastatic CRC.
Like
Save
Share